Sufferers of complex, chronic diseases like POTS and long COVID often spend years searching for relief. The longtime tech exec started ChronicleBio to find treatments using AI and lots of biological d...

A quarter of a century after what became known as “the Boom Boom Room” lawsuit, Wall Street still has a long way to go in giving women the respect they deserve.

New money and age-old injustice in an American river town.

Plus, the bond panic subsides.

A class of peptides that are meant to stimulate human growth hormone has been linked with a spat of severe allergic reactions and anaphylactic shock-like symptoms.

Reporters Committee rallied a coalition of 50 media outlets and industry groups in urging a federal court to restore White House access to the news outlets.

Alice Walton talks about why she's funding a major new Arkansas hospital in this week's Forbes innovationRx newsletter.

Memorial Sloan Kettering opens up its cancer data through OpenEvidence. Which healthcare and biotech entrepreneurs made the Forbes 400 for the first time. Persistent generic cancer drug shortages. The...

Memorial Sloan Kettering opens up its cancer data through OpenEvidence. Which healthcare and biotech entrepreneurs made the Forbes 400 for the first time. Persistent generic cancer drug shortages. The...

The oligarch, Umar Kremlev, spent hundreds of thousands on expenses like renting out a private island. He appears to have met Trump Jr. only recently, but he attended the intimate wedding with a large...

At his private golf clubs, the president barrels through foursomes, knocks away putts, and generally has the time of his life—with the government picking up the Secret Service’s hot-dog tab.

Patients sued by Senator Roger Marshall of Kansas were routinely charged 18 percent interest, The Times found. Some had bank accounts garnished.

Startup Inspiren is using AI and sensors to keep residents in assisted living and memory care healthier and out of the ER.

At a "practice of last resort," pediatricians prioritize allaying parents' vaccine concerns without hardline dismissals.

She challenged sexist assumptions, helping women develop a sense of self-worth and gain a measure of equality at work, at home and in society at large.

This week’s edition of InnovationRx looks at Vitestro’s newly authorized robot, Italy’s $10 billion pharma family, this year’s Covid-19 vaccines and more.

Over 100 years, Rome’s Angelini family built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market with the acquisition of Catalyst Ph...

In this week’s edition of InnovationRx, we look at Summa Health’s first tech bets, the healthcare leaders on Forbes Veteran 250 list, BioMarin’s acquisition of an early-stage bone disease therapy, and...

Apnimed got a new CEO in anticipation of its public offering. Its pill for sleep apnea could receive approval early next year.

Why does the owner of X get a pass for what he says and does there?

In this week’s edition of InnovationRx, we look at Fortell’s efforts to make a better hearing aid, Abby Care’s business getting payment for caregivers, J&J’s $5.5 billion talc settlement, Scribe Thera...

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming bonanza.

More than 600,000 police reports have been written with help from Axon’s AI tools. Public records obtained by Forbes show that they can introduce errors that cops have to spend time editing out.

The case appears to be the first to argue that a chatbot’s advice harmed someone seeking guidance about a medical condition.

In this week’s edition of InnovationRx, we look at the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a cancer-testing company...

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming bonanza.

The Trump administration has lost or abandoned hundreds of criminal cases against protesters and immigrants, a Times investigation found.

America’s salesman-in-chief capitalized on the most lucrative pitch of his life. Now Trump is selling something else—the myth that he doesn’t know how he made so much.

In this week’s edition of InnovationRx, Thyme Care gets new leadership, the intestinal illness spreads, Chai Discovery confirms its $400 million raise, and more.

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.

Cognyte, which sells technology to snoop on phone locations largely in Israel and Europe, is making inroads in America by tricking out trucks with spy tech.

The secretary of state effectively controls Venezuela’s finances, the distribution of its natural resources and its government. His grip on the country is a vivid manifestation of American power in th...

Ethics officials granted a waiver to an official who holds stocks in major technology companies.

In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more.

Desperate to rebuild his fortune, Donald Trump asked his political supporters to become his business partners. Those who trusted him most got hurt the worst.

Affordable Care Act plans are citing rising healthcare costs and falling enrollment.

The AI juggernaut is all-in on the healthcare industry, launching three new products in the last six months. But it needs to make sure ChatGPT is accurate enough for the millions of people who already...

In this week’s edition of InnovationRx, we look at Axsome’s growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more.

Scheduling doctor appointments is its own form of hell for both physicians and patients. Assort Health’s AI fix helped it raise its third venture round in 14 months.

Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to an experimental obesity drug through the agency’s “compassionate use” program.

Cadence reached a $1.2 billion valuation by using AI to track seniors’ chronic health conditions and improve their care.

The Iranian-French cartoonist and filmmaker was perhaps most well-known for the graphic memoir, and subsequent film, about her life during the Iranian revolution in 1979.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes h...